MAFLD
16
4
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (16)
Dihydroartemisinin for MAFLD
Incidence of Liver Disease-Related Outcomes in People With HIV
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
RE and Probiotics in MAFLD/NAFLD
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD
Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
AI Models vs Non-Invasive Fibrosis Scores in MAFLD Diagnosis
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice
Comparison of a Handheld Elastography Device With iLivTouch in Chronic Liver Disease Patients
A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver